The Management of Classical Hodgkin's Lymphoma: Past, Present, and Future

Table 3

Trials of treatments for early stage favourable Hodgkin’s lymphoma. Numbers in bold are statistically significant with 𝑃 values where significant. Abbreviations: OS: overall survival; EF RT: extended-field radiotherapy; IF-RT: involved-field radiotherapy; STLI: subtotal lymphoid irradiation; Gy: gray; ABVD: doxorubicin, bleomycin, vinblastine, and dacarbazine; AV: doxorubicin, vinblastine; EBVP: epirubicin, bleomycin, vinblastine, and prednisolone; MOPP/ABV: mechlorethamine, vincristine, procarbazine, prednisolone, doxorubicin, bleomycin, and vinblastine; SWOG: Southwest Oncology Group; GELA: Group d’Etudes des Lymphomes le l’Adulte; NCIC: National Cancer Institute of Canada; ECOG: Eastern Co-operative Oncology Group; MSKCC: Memorial Sloan Kettering Cancer Center.

Treatment regimen; (author/trial)	No. of Pts	Outcome; (%, measure, time)	OS (%)	Haem toxicity; (% Gr III-IV)	All acute toxicity; (% grade III-IV)	Second malignancy; (haem/solid, %)
STLI (36–40 Gy)	161	81 (FFS 3 y)	>95%	42	—	—
3AV + STLI (36–40 Gy)	165	94	>95%	57	—	—
(Press SWOG 2001)		𝑃<.001		𝑃=.004
EF RT 30 Gy (+10 Gy IF RT)	311	67 (FFTF 7 y)	92	0.8	—	3.2
2ABVD + EF RT 30 Gy (+10 Gy IF RT)	316	88	94	14.8	—	2.2
(Engert GHSG-HD7 2007)		𝑃<.001
STLI	165	78 (EFS 10 y)	92	—	—	1/2
6EBVP + IF RT (36–40 Gy)	168	88	92	—	—	1/0.01
(Noordijk EORTC-H7F 2006)		𝑃=.0113
STLI	272	74 (EFS 5 y)	92 (10 y)	—	—	0/2
3MOPP/ABV + IF RT (36 Gy)	270	98	97	—	—	0/2
(Ferme EORTC/GELA-H8F 2007)		𝑃<.001	𝑃<.001
4ABVD + STLI RT	136	93 (12 y FFP)	96	—	—	1.5/3
4ABVD + IF RT		94	94	—	—	—
(Bonadonna Milan 2004)
4ABVD + IF RT	1370	93 (FFTF 5 y)	97	24	52
2ABVD + IF RT		91	97	15	33
ABVD + IF RT (30 Gy)		93	98		8.7
ABVD + IF RT (20 Gy)		93	93		2.9
(Engert GHSG-HD10 2009)
STLI	64	88 (5 y FFP)	100	—	—	—
4–6ABVD	59	87	97	—	—	—
(Meyer NCIC/ECOG HD6 2005)
6ABVD + IF/EF RT	76	86 (5 y FFP)	97
6ABVD	76	81	90
(Straus MSKCC 2004)